Hugel (145020) Q1 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q1 2026 earnings summary
7 May, 2026Executive summary
Net sales for 1Q26 reached KRW 116.6bn, up 29.9% year-over-year.
Operating profit rose 22.3% year-over-year to KRW 47.6bn.
Net income increased 31.5% year-over-year to KRW 40.6bn.
Financial highlights
Gross profit for 1Q26 was KRW 90.1bn, up 30.5% year-over-year, with a gross margin of 77.2%.
SG&A expenses increased 41.2% year-over-year to KRW 42.5bn.
Pre-tax income rose 36.6% year-over-year to KRW 56.1bn.
Outlook and guidance
International sales momentum remains strong, especially in North & South America and Asia Pacific.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Hugel
- Operating profit surged 54.5% year-over-year on strong toxin and international sales growth.145020
Q3 20247 May 2026 - Double-digit sales and profit growth in 4Q24, led by Toxin, Filler, and Cosmetics segments.145020
Q4 20247 May 2026 - Strong international sales fueled 17% revenue growth and 73% net income surge in 2Q24.145020
Q2 20247 May 2026 - Global expansion, strong financials, and innovation drive leadership in medical aesthetics.145020
J.P. Morgan HealthCare Conference 2025 presentation7 May 2026 - Targeting global leadership in aesthetics with innovative products and a hybrid U.S. sales model.145020
JP Morgan Healthcare Conference 2026 presentation7 May 2026 - Strong international growth led to a 21.3% YoY sales increase in 4Q25, despite lower net income.145020
Q4 202511 Feb 2026 - 3Q25 saw flat sales, lower profit, strong international growth, and robust Derma Cosmetics.145020
Q3 20254 Nov 2025 - Botulinum toxin and derma cosmetics drove double-digit sales growth, led by surging exports.145020
Q2 20256 Aug 2025 - 1Q25 revenue and net income surged, led by strong Asia Pacific and product growth.145020
Q1 20256 Jun 2025